Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
To date, only 37 of 194 countries that signed up to implement the WHO Global action plan on dementia have created and funded national dementia plans. Our new campaign aims to galvanise and encourage more governments to develop national dementia plans following their 2017 commitment.
The news follows a negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting.
Eisai’s lecanemab will represent the second anti-Amyloid Beta therapy to be evaluated by the FDA as a disease modifying treatment for early Alzheimer’s disease.
This report reviews progress towards the implementation of the 7 action areas of the plan by Member States, WHO and civil society, and all those involved in tackling the dementia pandemic.
ADI members in the Middle East region took part in their first regional meeting of 2021 and since the COVID-19 pandemic began in early 2020.
ADI members in the African region took part in their first regional meeting of 2021 and since the COVID-19 pandemic began in early 2020.
The World Alzheimer Report 2020 has been awarded the European Healthcare Design (EHD) 2021 Award for Outstanding Contribution to Global Knowledge.
Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.